Compare Analog Devices, Inc. (ADI) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Amylx Pharmaceuticals Inc — how do they compare? Analog Devices, Inc. trades at $388.56 (market cap $187.67B), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B). The key difference: Analog Devices, Inc. is far larger — about 71.1× Amylx Pharmaceuticals Inc's market cap, and Analog Devices, Inc. pays a 1.14% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ADI | AMLX | |
|---|---|---|
Market Cap | $187.67B | $2.64B |
Sector | Technology | Health |
52-Week High | $445.48 | $24.19 |
52-Week Low | $225.20 | $7.82 |
Enterprise Value | $192.92B | $2.39B |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $383.93, down 1.54% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 26.01% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights institutional buying and a spin-off of ADI Global Distribution, completed August 4, 2026, as per a Business Wire report.
The outlook is positive, supported by a strong analyst consensus with a $472.29 price target and no sell ratings. Key opportunities include consistent earnings outperformance and exposure to semiconductor sector growth. Risks involve high valuation multiples and potential market volatility impacting the stock's premium pricing.
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
